Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Transcode Therapeutics, Inc. in our court records and SEC 8-K records (as of 2026-10-18).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Ck Life Sciences Int'L., (Holdings) Inc. (filed 2026-08-03).
Who is behind it
Transcode Therapeutics, Inc.: incorporated in Delaware; business address in Boston, Massachusetts; industry Pharmaceutical Preparations (Schedule 13D/A, 2026-08-03).
Officers and directors, each with the role and the filing that names them:
- Thomas A. Fitzgerald: Executive Officer, Director (Form D, 2024-12-12)
- Erik Manting: Director (Form D, 2024-12-12)
- Magda Marquet: Director (Form D, 2024-12-12)
- Philippe Calais: Director (Form D, 2024-12-12)
| Report | Holder | Share |
|---|---|---|
| Schedule 13D/A, 2026-08-03 | Ck Life Sciences Int'L., (Holdings) Inc. | 83.9% |
| Schedule 13G, 2026-07-28 | Elena Rosa Braci | 6.17% |
| Schedule 13G, 2026-07-28 | Daniel Eduardo Katzman | 5.16% |
| Schedule 13G, 2026-07-28 | Unleash Immuno Oncolytics, Inc. | 9.94% |
| Schedule 13D/A, 2026-07-27 | Ck Life Sciences Int'L., (Holdings) Inc. | 83.9% |
| Schedule 13D/A, 2026-07-23 | Ck Life Sciences Int'L., (Holdings) Inc. | 9.9% |
| Schedule 13D/A, 2026-07-17 | Ck Life Sciences Int'L., (Holdings) Inc. | 8.8% |
| Schedule 13G, 2026-04-20 | Ya Ii Pn, LTD. | 9.9% |
Money raised
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2024-12-12 | $8M | $8M |
Latest IPO step: Transcode Therapeutics, Inc. filed to go public (S-1, 2026-05-01).
IPO filings: S-1, 2026-05-01, S-1, 2024-12-06; ticker RNAZ on Nasdaq Capital Market.
Acquisitions reported on Form 8-K, Item 2.01: completed an acquisition (2025-10-08).
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/transcode-therapeutics